-DOCSTART- -X- O
INTRODUCTION -X- _ O
: -X- _ O
The -X- _ O
precise -X- _ O
role -X- _ O
of -X- _ O
cytomegalovirus -X- _ B-Intervention
( -X- _ I-Intervention
CMV -X- _ I-Intervention
) -X- _ I-Intervention
infection -X- _ I-Intervention
in -X- _ O
contributing -X- _ O
to -X- _ O
outcomes -X- _ O
in -X- _ O
critically -X- _ B-Patient
ill -X- _ I-Patient
immunocompetent -X- _ I-Patient
patients -X- _ I-Patient
has -X- _ O
not -X- _ O
been -X- _ O
fully -X- _ O
defined. -X- _ O
METHODS -X- _ O
: -X- _ O
Studies -X- _ O
in -X- _ O
which -X- _ O
critically -X- _ B-Patient
ill -X- _ I-Patient
immunocompetent -X- _ I-Patient
adults -X- _ I-Patient
were -X- _ O
monitored -X- _ O
for -X- _ O
CMV -X- _ B-Intervention
infection -X- _ I-Intervention
in -X- _ O
the -X- _ O
intensive -X- _ O
care -X- _ O
unit -X- _ O
( -X- _ O
ICU -X- _ O
) -X- _ O
were -X- _ O
reviewed. -X- _ O
RESULTS -X- _ O
: -X- _ O
CMV -X- _ B-Outcome
infection -X- _ I-Outcome
occurs -X- _ I-Outcome
in -X- _ I-Outcome
0 -X- _ I-Outcome
to -X- _ I-Outcome
36 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
critically -X- _ I-Outcome
ill -X- _ I-Outcome
patients -X- _ I-Outcome
, -X- _ O
mostly -X- _ O
between -X- _ O
4 -X- _ O
and -X- _ O
12 -X- _ O
days -X- _ O
after -X- _ O
ICU -X- _ O
admission. -X- _ O
Potential -X- _ O
risk -X- _ B-Outcome
factors -X- _ I-Outcome
for -X- _ I-Outcome
CMV -X- _ I-Outcome
infection -X- _ I-Outcome
include -X- _ I-Outcome
sepsis -X- _ I-Outcome
, -X- _ I-Outcome
requirement -X- _ I-Outcome
of -X- _ I-Outcome
mechanical -X- _ I-Outcome
ventilation -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
transfusions. -X- _ I-Outcome
Prolonged -X- _ O
mechanical -X- _ O
ventilation -X- _ O
( -X- _ O
21 -X- _ O
to -X- _ O
39 -X- _ O
days -X- _ O
vs. -X- _ O
13 -X- _ O
to -X- _ O
24 -X- _ O
days -X- _ O
) -X- _ O
and -X- _ O
duration -X- _ O
of -X- _ O
ICU -X- _ O
stay -X- _ O
( -X- _ O
33 -X- _ O
to -X- _ O
69 -X- _ O
days -X- _ O
vs. -X- _ O
22 -X- _ O
to -X- _ O
48 -X- _ O
days -X- _ O
) -X- _ O
correlated -X- _ O
significantly -X- _ O
with -X- _ O
a -X- _ O
higher -X- _ O
risk -X- _ O
of -X- _ O
CMV -X- _ O
infection. -X- _ O
Mortality -X- _ B-Outcome
rates -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
CMV -X- _ I-Outcome
infection -X- _ I-Outcome
were -X- _ I-Outcome
higher -X- _ I-Outcome
in -X- _ I-Outcome
some -X- _ I-Outcome
but -X- _ I-Outcome
not -X- _ I-Outcome
all -X- _ I-Outcome
studies. -X- _ I-Outcome
Whether -X- _ O
CMV -X- _ O
produces -X- _ O
febrile -X- _ O
syndrome -X- _ O
or -X- _ O
end-organ -X- _ O
disease -X- _ O
directly -X- _ O
in -X- _ O
these -X- _ O
patients -X- _ O
is -X- _ O
not -X- _ O
known. -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
CMV -X- _ B-Outcome
infection -X- _ I-Outcome
frequently -X- _ I-Outcome
occurs -X- _ I-Outcome
in -X- _ I-Outcome
critically -X- _ I-Outcome
ill -X- _ I-Outcome
immunocompetent -X- _ I-Outcome
patients -X- _ I-Outcome
and -X- _ I-Outcome
may -X- _ I-Outcome
be -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
poor -X- _ I-Outcome
outcomes. -X- _ I-Outcome
Further -X- _ O
studies -X- _ O
are -X- _ O
warranted -X- _ O
to -X- _ O
identify -X- _ O
subsets -X- _ O
of -X- _ O
patients -X- _ O
who -X- _ O
are -X- _ O
likely -X- _ O
to -X- _ O
develop -X- _ O
CMV -X- _ O
infection -X- _ O
and -X- _ O
to -X- _ O
determine -X- _ O
the -X- _ O
impact -X- _ O
of -X- _ O
antiviral -X- _ O
agents -X- _ O
on -X- _ O
clinically -X- _ O
meaningful -X- _ O
outcomes -X- _ O
in -X- _ O
these -X- _ O
patients -X- _ O
. -X- _ O

